Dr. C.A.J.M. Gaillard
 | | Cardiovasculair risico en anemie bij patienten met chronische nierschade en type 2 diabetes |
|
|
 | | TREAT Wat vooraf ging |
|
|
 | | 1989 |
|  | | TREAT Wat vooraf ging |
|
 | | November 16, 2006 |
|  | | Slide 8 |
|
 | | FDA warnings |
|  | | Nieuwe Target 6,8-7,4 Start 6,2 |
|
 | | Target Hb Values in International Guidelines |
|  | | What is the Optimal Target Hb ? |
|
 | | TREAT: Trial to Reduce Cardiovascular Events With Aranesp® (Darbepoetin alfa) Therapy |
|  | | Primary Endpoints |
|
 | | Other Secondary Endpoints |
|  | | Cardiovascular-Related Patient Characteristics: Darbepoetin alfa Versus Placebo |
|
 | | Mean Hemoglobin Levels |
|  | | “Placebo” Hb effect Hb stijgt in placebo groep |
|
 | | Cardiovascular Composite End Point |
|  | | Fatal or Nonfatal Stroke |
|
 | | Composite and Component End Points |
|  | | Stroke Vragen |
|
 | | Post-Hoc Analysis of Patients With a Prior History of Cancer |
|  | | Other outcomes |
|
 | | Wat betekenen deze resultaten? |
|  | | Slide 26 |
|
 | | Een groene zone? |
|  | | Wat weten we |
|
 | | Welke vragen zijn er nu |
|  | | Mijn conclusies |
|
 | | Take home message(s): |
|
Deel deze pagina met collega's en vrienden: